endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners UNITAID and the Transformational Investment Capacity (TIC) of MSF. 

Watch the two-minute animation

 

You can contact us, or follow us on Twitter.

DR-TB Drugs Under the Microscope: 8th edition

DRTB drugs under the microscope

This MSF Access Campaign report – the eighth in this series – examines the current landscape and trends of DR-TB drug pricing and patents, and highlights challenges and opportunities to accelerate people’s access to lifesaving regimens that are shorter, all-oral and make use of the most effective medicines. 

 

pdf

endTB Statement on WHO Rapid Communication on key changes to the treatment of drug-resistant tuberculosis

WHO rapid comms

 

8 June 2022

Read more

PIH MSF MSF UNITAID Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo